Related Experiment Video
Updated: Apr 28, 2026
Author Spotlight: Understanding Chronic Lung Diseases Using 3D Printed Phototunable Hydrogels
Published on: June 30, 2023
HYAL3 as a therapeutic target for pulmonary arterial Hypertension-Cardiomyopathy comorbidity: an integrative analysis
Jianchuan Hu1, Wanqun Zhang2, Qiurong Zeng1
1General Practice Department, Chongqing University Fuling Hospital, Chongqing University, Chongqing, China.
Background:
This study aimed to elucidate the molecular mechanisms driving the comorbidity of pulmonary arterial hypertension and cardiomyopathy (PAH-CMP), identify key pathogenic genes, and explore potential therapeutic agents targeting these genes.
Methods:
Common targets for PAH and CMP were retrieved from public databases. Weighted gene co-expression network analysis (WGCNA) and multiple machine learning algorithms were employed to screen diagnostic hub genes. Upstream regulatory networks were constructed to explore molecular interactions. Key findings were validated in vitro using hypoxia-induced human pulmonary artery endothelial cells (HPAECs) and angiotensin II-induced H9C2 cardiomyocytes. Finally, molecular docking and dynamics simulations were performed to identify drug candidates.
Results:
In total, 14,403 genes common to PAH and CMP were identified. WGCNA identified a key module that was strongly correlated with PAH-CMP. Integrative machine learning highlighted four hub genes, HYAL3, ADIPOQ, ZNF852, and SCD, all of which showed excellent diagnostic value for PAH-CMP comorbidity, with an area under curve exceeding 0.9. Regulatory network analysis revealed potential upstream transcription factors, including FOXL1, FOXC1, and PPARG. The SHAP analysis demonstrated the strong contribution of these genes to the model, with HYAL3 exhibiting the highest feature importance. Experimental validation confirmed that HYAL3 was significantly upregulated in both the PAH endothelial cell model and the CMP cardiomyocyte model, corroborating the bioinformatic predictions. Virtual screening identified flurbiprofen as a high-affinity binder for HYAL3, and molecular dynamics simulations demonstrated stable binding between them.
Conclusion:
This study systematically identified and experimentally validated HYAL3, ADIPOQ, ZNF852, and SCD as core genes in PAH-CMP comorbidity and proposed flurbiprofen as a candidate therapeutic agent targeting HYAL3. Our findings provide mechanistic insights and a potential pharmacological strategy for the treatment of PAH-CMP.
More Related Videos
Related Concept Videos
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:30Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...